These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20950615)

  • 1. IL28B and the control of hepatitis C virus infection.
    Balagopal A; Thomas DL; Thio CL
    Gastroenterology; 2010 Dec; 139(6):1865-76. PubMed ID: 20950615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.
    Berger CT; Kim AY
    Infect Dis Clin North Am; 2012 Dec; 26(4):863-77. PubMed ID: 23083820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.
    Bellanti F; Vendemiale G; Altomare E; Serviddio G
    Clin Dev Immunol; 2012; 2012():849373. PubMed ID: 22966241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic HCV infection.
    Meng Q; Rani MR; Sugalski JM; Judge CJ; Phat S; Rodriguez B; Blanton RE; Anthony DD
    J Infect Dis; 2014 May; 209(10):1591-601. PubMed ID: 24302757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
    Naggie S; Osinusi A; Katsounas A; Lempicki R; Herrmann E; Thompson AJ; Clark PJ; Patel K; Muir AJ; McHutchison JG; Schlaak JF; Trippler M; Shivakumar B; Masur H; Polis MA; Kottilil S
    Hepatology; 2012 Aug; 56(2):444-54. PubMed ID: 22331604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.
    Rallón NI; Soriano V; Naggie S; Restrepo C; McHutchison J; Vispo E; Benito JM
    J Antimicrob Chemother; 2012 May; 67(5):1246-9. PubMed ID: 22294646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate immunity and HCV.
    Heim MH
    J Hepatol; 2013 Mar; 58(3):564-74. PubMed ID: 23063572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.
    Thomas DL; Thio CL; Martin MP; Qi Y; Ge D; O'Huigin C; Kidd J; Kidd K; Khakoo SI; Alexander G; Goedert JJ; Kirk GD; Donfield SM; Rosen HR; Tobler LH; Busch MP; McHutchison JG; Goldstein DB; Carrington M
    Nature; 2009 Oct; 461(7265):798-801. PubMed ID: 19759533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
    Watanabe T; Sugauchi F; Tanaka Y; Matsuura K; Yatsuhashi H; Murakami S; Iijima S; Iio E; Sugiyama M; Shimada T; Kakuni M; Kohara M; Mizokami M
    Gut; 2013 Sep; 62(9):1340-6. PubMed ID: 23135762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment.
    Riva E; Scagnolari C; Turriziani O; Antonelli G
    Clin Microbiol Infect; 2014 Dec; 20(12):1237-45. PubMed ID: 25273834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.
    Maekawa S; Sakamoto M; Miura M; Kadokura M; Sueki R; Komase K; Shindo H; Komatsu N; Shindo K; Kanayama A; Ohmori T; Amemiya F; Takano S; Yamaguchi T; Nakayama Y; Kitamura T; Inoue T; Okada S; Enomoto N
    Hepatology; 2012 Nov; 56(5):1611-21. PubMed ID: 22577043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Matsuura K; Watanabe T; Tanaka Y
    J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The function and application of the IL28B gene in HCV infection and treatment].
    Ma K; Zhang AM; Xia XS
    Yi Chuan; 2013 Nov; 35(11):1244-52. PubMed ID: 24579307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
    El Awady MK; Bader El Din NG; Tabll A; El Hosary Y; Abdel Aziz AO; El Khayat H; Salama M; Abdelhafez TH
    World J Gastroenterol; 2013 Jan; 19(2):290-8. PubMed ID: 23345953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
    de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA
    PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.